RecruitingNCT06569589

Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat

Tissue Sodium Quantification in Patients With Primary Aldosteronism


Sponsor

Jens Titze

Enrollment

80 participants

Start Date

Dec 27, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.


Eligibility

Min Age: 21 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study uses a special type of MRI to measure how much sodium is stored in the body's tissues in people with primary aldosteronism — a condition where the adrenal glands produce too much aldosterone, a hormone that causes the body to retain sodium and raise blood pressure. High tissue sodium may contribute to heart and kidney damage. **You may be eligible if:** - You are between 21 and 70 years old with high blood pressure, or you are suspected of having primary aldosteronism based on specialist guidelines - You are willing and able to consent **You may NOT be eligible if:** - You have implanted metal devices (pacemaker, cochlear implant, surgical clips, etc.) that are not MRI-safe - You have iron-based tattoos or other metal in your body - You feel very anxious in enclosed spaces (claustrophobia) - You are pregnant - You have severe heart failure (NYHA class III or IV) - Your kidney function is significantly reduced (eGFR below 30) or you have significant protein in the urine - You have severe liver disease or muscular dystrophies Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST23NaMRI Scan

23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.

DIETARY_SUPPLEMENTPotassium Chloride (KCl)

K+ supplementation intervention is given participants as part of their standard care. In this trial the K+ supplementation dosage is standardized and adjusted based on blood K+ level


Locations(4)

Singapore General Hospital

Singapore, Singapore

Duke NUS Medical School

Singapore, Singapore

Changi General Hospital

Singapore, Singapore

Sengkang General Hospital

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06569589


Related Trials